213 related articles for article (PubMed ID: 22223528)
1. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Margolin KA; Moon J; Flaherty LE; Lao CD; Akerley WL; Othus M; Sosman JA; Kirkwood JM; Sondak VK
Clin Cancer Res; 2012 Feb; 18(4):1129-37. PubMed ID: 22228638
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).
Slingluff CL; Petroni GR; Molhoek KR; Brautigan DL; Chianese-Bullock KA; Shada AL; Smolkin ME; Olson WC; Gaucher A; Chase CM; Grosh WW; Weiss GR; Wagenseller AG; Olszanski AJ; Martin L; Shea SM; Erdag G; Ram P; Gershenwald JE; Weber MJ
Clin Cancer Res; 2013 Jul; 19(13):3611-20. PubMed ID: 23620404
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T; Marais R; Affolter A; Lorigan P; Robert C; Corrie P; Ottensmeier C; Chevreau C; Chao D; Nathan PD; Jouary T; Harries M; Negrier S; Montegriffo E; Ahmad T; Gibbens I; James MG; Strauss UP; Prendergast S; Gore ME
Br J Cancer; 2011 Jul; 105(3):353-9. PubMed ID: 21750549
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Eisen T; Ahmad T; Flaherty KT; Gore M; Kaye S; Marais R; Gibbens I; Hackett S; James M; Schuchter LM; Nathanson KL; Xia C; Simantov R; Schwartz B; Poulin-Costello M; O'Dwyer PJ; Ratain MJ
Br J Cancer; 2006 Sep; 95(5):581-6. PubMed ID: 16880785
[TBL] [Abstract][Full Text] [Related]
9. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
10. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Lee EQ; Kuhn J; Lamborn KR; Abrey L; DeAngelis LM; Lieberman F; Robins HI; Chang SM; Yung WK; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados MD; Cloughesy TF; Gilbert MR; Wen PY
Neuro Oncol; 2012 Dec; 14(12):1511-8. PubMed ID: 23099651
[TBL] [Abstract][Full Text] [Related]
15. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Flaherty KT; Manola JB; Pins M; McDermott DF; Atkins MB; Dutcher JJ; George DJ; Margolin KA; DiPaola RS
J Clin Oncol; 2015 Jul; 33(21):2384-91. PubMed ID: 26077237
[TBL] [Abstract][Full Text] [Related]
16. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
18. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M; Mlineritsch B; Ressler S; Moik M; Kappacher A; Rosenlechner S; Greil R
Oncology; 2011; 80(1-2):34-41. PubMed ID: 21606662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
